Department of Urology, Rennes University Hospital, CHU Pontchaillou, rue Henri le Guillou, 35033, Rennes, France,

This email address is being protected from spam bots, you need Javascript enabled to view it

To present an update on anti-angiogenic drugs in the treatment of metastatic renal cell carcinoma.

A better understanding of molecular pathways that are involved in clear cell carcinomas has led to the development of multiple targeted therapies with significant clinical benefits. Two tyrosine kinase inhibitors targeting the vascular endothelial growth factor (VEGF) receptor have been shown to improve the progression-free survival of patients in first-line (Sunitinib vs. interferon-alpha) or second-line treatment (Sorafenib vs. placebo). Temsirolimus, an agent that inhibits the serine-threonine kinase activity of the mammalian target of rapamycin, offers better overall survival than interferon in patients with poor-risk characteristics. Finally, Bevacizumab, which is an antibody directed against VEGF, in association with IFN is providing substantial response rates and increased progression-free survival compared to IFN alone.

Four major drugs or regimens with proven efficacy are now available in first and second line therapy in metastatic renal cell carcinoma (mRCC). Further studies are needed to determine the optimal combinations of these agents in metastatic disease and to assess their impact in the adjuvant setting.

Written by
Patard JJ, Pouessel D, Bensalah K, Culine S.

Reference
World J Urol. 2008 Feb 12. Epub ahead of print.
doi:10.1007/s00345-008-0237-4

PubMed Abstract
PMID:18265991

UroToday.com Renal Cancer Section

Please log-in or register in order to submit comments.

Powered by AkoComment!